JP2018203747A5 - - Google Patents

Download PDF

Info

Publication number
JP2018203747A5
JP2018203747A5 JP2018150978A JP2018150978A JP2018203747A5 JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5 JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018150978 A JP2018150978 A JP 2018150978A JP 2018203747 A5 JP2018203747 A5 JP 2018203747A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
cholesterol
diabetes
use according
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018150978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018203747A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018203747A publication Critical patent/JP2018203747A/ja
Publication of JP2018203747A5 publication Critical patent/JP2018203747A5/ja
Priority to JP2021103893A priority Critical patent/JP2021155436A/ja
Priority to JP2023146755A priority patent/JP2023178518A/ja
Pending legal-status Critical Current

Links

JP2018150978A 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法 Pending JP2018203747A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021103893A JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015505963A Division JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103893A Division JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法

Publications (2)

Publication Number Publication Date
JP2018203747A JP2018203747A (ja) 2018-12-27
JP2018203747A5 true JP2018203747A5 (https=) 2019-05-16

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (https=)
EP (2) EP4299121A3 (https=)
JP (4) JP6491089B2 (https=)
CN (2) CN111419870A (https=)
CA (1) CA2870316C (https=)
ES (1) ES2959119T3 (https=)
MX (2) MX371073B (https=)
WO (1) WO2013155485A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
CN111973484A (zh) 2013-03-12 2020-11-24 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
WO2021096998A1 (en) * 2019-11-11 2021-05-20 Atsuo Ochi Method and a kit to reprogram somatic cells
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US20240000826A1 (en) * 2020-08-27 2024-01-04 Beren Therapeutics P.B.C. Methods for the treatment of cardiovascular disease with cyclodextrins
MX2023002420A (es) * 2020-08-27 2023-07-11 Beren Therapeutics P B C Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.
KR20230096975A (ko) * 2020-08-27 2023-06-30 베렌 테라퓨틱스 피.비.씨. 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116322710A (zh) * 2021-09-01 2023-06-23 株式会社雷纳图斯 包括γ-环糊精聚合物的药物组合物以及其用途
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6756504B2 (en) 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PL220776B1 (pl) 2002-08-19 2016-01-29 Soho Flordis Internat Pty Ltd Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
AU2006208108A1 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including NDGA compounds
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008067027A2 (en) * 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CN102438614A (zh) * 2008-10-10 2012-05-02 利默里克生物制药公司 用于治疗的吡喃酮类似物
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
WO2010103823A1 (ja) 2009-03-12 2010-09-16 パナソニック株式会社 画像表示装置および画像表示方法
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
WO2011057172A1 (en) 2009-11-06 2011-05-12 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
WO2012054321A2 (en) * 2010-10-19 2012-04-26 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
MX371073B (es) * 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.

Similar Documents

Publication Publication Date Title
US20230338412A1 (en) Method of using cyclodextrin
JP2018203747A5 (https=)
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Liang et al. Andrographolide Ameliorates Diabetic Cardiomyopathy in Mice by Blockage of Oxidative Damage and NF‐κB‐Mediated Inflammation
Pisciotta et al. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
ES2307729T3 (es) Modulacion de un perfil lipidico con esteroides y agonistas de ppar alfa.
US20100227841A1 (en) Patient populations and treatment methods
CN105008394A (zh) 治疗结肠直肠癌的方法
US20250262190A1 (en) Use of lat1 inhibitors to treat obesity
KR102218498B1 (ko) Fxr 작용제들의 조합물
KR20190044667A (ko) Fxr 작용제의 신규 요법
US10758551B2 (en) Methods and compositions for treating pancreatitis
Zhou et al. Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells
HK40032085A (en) Method of using cyclodextrin
WO2011153209A2 (en) Cd36 inhibition to control obesity and insulin sensitivity
US20080020982A1 (en) Methods and compositions for treatment of atherosclerosis
Liu et al. Erythropoietin alleviate obstructive renal fibrosis by regulating immunity and inflammation through miR-21-5p/SPRY1/ERK1/2/NF-κB pathway inhibition
WO2025096597A1 (en) Compositions including inhibitors of pten expression or activity to prevent or treat type 2 diabetes
WO2026082873A1 (en) Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease